DK1109453T3 - Sammensætninger og fremgangsmåder til behandling af mitokondrielle sygdomme - Google Patents

Sammensætninger og fremgangsmåder til behandling af mitokondrielle sygdomme

Info

Publication number
DK1109453T3
DK1109453T3 DK99968207.3T DK99968207T DK1109453T3 DK 1109453 T3 DK1109453 T3 DK 1109453T3 DK 99968207 T DK99968207 T DK 99968207T DK 1109453 T3 DK1109453 T3 DK 1109453T3
Authority
DK
Denmark
Prior art keywords
procedures
compositions
mitochondrial diseases
treating mitochondrial
treating
Prior art date
Application number
DK99968207.3T
Other languages
English (en)
Inventor
Borstel Reid W Von
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Application granted granted Critical
Publication of DK1109453T3 publication Critical patent/DK1109453T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
DK99968207.3T 1998-08-31 1999-08-31 Sammensætninger og fremgangsmåder til behandling af mitokondrielle sygdomme DK1109453T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/144,096 US6472378B2 (en) 1998-08-31 1998-08-31 Compositions and methods for treatment of mitochondrial diseases
PCT/US1999/019725 WO2000011952A1 (en) 1998-08-31 1999-08-31 Compositions and methods for treatment of mitochondrial diseases

Publications (1)

Publication Number Publication Date
DK1109453T3 true DK1109453T3 (da) 2012-11-19

Family

ID=22507021

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99968207.3T DK1109453T3 (da) 1998-08-31 1999-08-31 Sammensætninger og fremgangsmåder til behandling af mitokondrielle sygdomme

Country Status (18)

Country Link
US (5) US6472378B2 (da)
EP (2) EP2295063B1 (da)
JP (2) JP4717209B2 (da)
KR (2) KR20010085746A (da)
CN (2) CN1636572B (da)
AU (1) AU753203B2 (da)
BR (1) BR9913319A (da)
CA (3) CA2341700C (da)
CY (1) CY1113610T1 (da)
DK (1) DK1109453T3 (da)
ES (1) ES2393065T3 (da)
HU (1) HU230066B1 (da)
IL (2) IL141429A0 (da)
NZ (2) NZ586365A (da)
PT (1) PT1109453E (da)
RU (2) RU2279880C2 (da)
WO (1) WO2000011952A1 (da)
ZA (1) ZA200101565B (da)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776838B1 (en) * 1987-10-28 2010-08-17 Wellstat Therapeutics Corporation Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US6306909B1 (en) 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
US20020006913A1 (en) 1997-11-04 2002-01-17 Von Borstel Reid W. Antimutagenic compositions for treatment and prevention of photodamage to skin
US8518882B2 (en) * 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US20050203053A1 (en) * 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US8143234B2 (en) * 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
DK1870103T3 (da) * 1998-07-31 2010-01-11 Massachusetts Inst Technology Anvendelse af uridin i kombination med cholin i behandling af hukommelsesforsstyrrelse
US8314064B2 (en) * 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
US20060069061A1 (en) * 1998-07-31 2006-03-30 Dick Wurtman Compositions containing uridine and choline, and methods utilizing same
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US7807654B2 (en) * 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
BR0008447A (pt) 1999-02-23 2002-01-15 Univ California Métodos de tratamento de distúrbios mitocondriais
US6616942B1 (en) 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
US6878514B1 (en) * 1999-03-30 2005-04-12 Purdue Research Foundation Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof
WO2001021208A1 (en) 1999-09-23 2001-03-29 Juvenon Corporation Nutritional supplement for increased energy and stamina
US6562869B1 (en) 1999-09-23 2003-05-13 Juvenon, Inc. Nutritional supplement for increased energy and stamina
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
US6727231B1 (en) 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
AUPR177300A0 (en) * 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
JP2005506042A (ja) 2000-12-12 2005-03-03 ユニヴァーシティー オブ コネティカット 細胞トランスポーターをコードするポリヌクレオチド、およびその使用方法
DE10110355A1 (de) * 2001-03-03 2002-09-12 Ulrich Walker Bekämpfung von Nebenwirkungen
US7501429B2 (en) * 2001-04-11 2009-03-10 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
WO2002083651A2 (en) * 2001-04-11 2002-10-24 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
CA2448160A1 (en) * 2001-05-25 2002-12-05 Queen's University At Kingston Heterocyclic beta-amino acids and their use as anti-epileptogenic agents
CN1551778A (zh) 2001-09-05 2004-12-01 ɽ����ʽ���� 用于糖尿病神经病变的药物组合物
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
AU2002339696A1 (en) * 2001-12-03 2003-06-17 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
AUPR951101A0 (en) * 2001-12-13 2002-01-24 Centre For Molecular Biology And Medicine Method of treatment
CA2492725A1 (en) * 2002-07-11 2004-01-22 Yamasa Corporation Medicinal composition for drug-induced neuropathy
RU2238558C2 (ru) * 2002-09-11 2004-10-20 Государственный НИИ курортологии Способ оценки функционального состояния больных синдромом хронической усталости
CN101440124B (zh) * 2003-02-04 2012-07-18 科内尔研究基金会 用于防止线粒体通透性改变的方法
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
WO2005033092A1 (en) * 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
WO2005032278A1 (en) 2003-09-29 2005-04-14 Soft Gel Technologies, Inc. SOLUBILIZED CoQ-10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
AU2004293477A1 (en) * 2003-11-25 2005-06-09 University Of Rochester Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
US20060160748A1 (en) * 2003-11-25 2006-07-20 Shey-Shing Sheu Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
KR101242486B1 (ko) * 2004-01-12 2013-03-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 장기 전달을 위한 제형 및 그의 이용 방법
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
CA3024434A1 (en) 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
WO2005077040A2 (en) * 2004-02-11 2005-08-25 Rensselaer Polytechnic Institute Compositions and methods for treating amyotrophic lateral sclerosis (als)
EP1750509A4 (en) * 2004-05-13 2010-03-24 Massachusetts Inst Technology EFFECTS OF URIDINE ON DOPAMINE RELIEF
WO2005122767A1 (en) 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
KR100675225B1 (ko) * 2004-06-28 2007-01-26 대림산업 주식회사 차음성능 및 단열성능 향상을 위한 경량벽체 시스템 및 그설치방법
CA2575367A1 (en) * 2004-07-28 2006-02-23 Board Of Regents, The University Of Texas System 3-halo-2-oxopropionate salts and esters as novel anticancer agents
US7947661B2 (en) 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
AU2005285090A1 (en) * 2004-09-15 2006-03-23 Massachusetts Institute Of Technology Compositions containing uridine, and methods utilizing same
US8415388B2 (en) * 2005-02-22 2013-04-09 Savvipharm Inc. Pharmaceutical compositions containing paclitaxel orotate
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
US8258181B2 (en) * 2005-03-23 2012-09-04 Florida Atlantic University Treatment or prevention of cancer and precancerous disorders
US8357720B2 (en) * 2005-03-23 2013-01-22 Florida Atlantic University Treatment or prevention of cancer and precancerous disorders
AU2006244374B2 (en) * 2005-05-06 2012-01-19 University Of Kentucky Research Foundation Nanotubes as mitochondrial uncouplers
CA2645645C (en) * 2005-05-23 2015-07-14 Massachusetts Institute Of Technology Compositions containing pufa and methods of use thereof
RU2429851C2 (ru) * 2005-05-23 2011-09-27 Массачусетс Инститьют Оф Текнолоджи Композиции, содержащие pufa и/или уридин, и способы их применения
EA035619B1 (ru) 2005-06-01 2020-07-16 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Композиции для использования в способе лечения митохондриальных нарушений
US20090298782A1 (en) * 2005-12-20 2009-12-03 University Of Rochester Compounds for Delivering Amino Acids or Peptides with Antioxidant Activity into Mitochondria and Use Thereof
EP1986636B1 (en) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
KR20080104329A (ko) * 2006-02-22 2008-12-02 아놀드 뮤니히 데페리프론의 이용 및 철의 세포 내 미스핸들링으로부터 비롯된 프리드리히 운동실조증의 치료 및/또는 예방 방법
KR100801057B1 (ko) * 2006-07-18 2008-02-04 삼성전자주식회사 컬러 보정 블럭을 구비하는 ｃｍｏｓ 이미지 센서 및 그이미지 센싱 방법
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
WO2008116301A1 (en) 2007-03-28 2008-10-02 Apotex Technologies Inc. Fluorinated derivatives of deferiprone
BRPI0817387A2 (pt) * 2007-11-02 2015-09-08 Massachusetts Inst Technology métodos de conformidade de suplementação dietária de uridina e uso dos mesmos
NZ584656A (en) * 2007-11-09 2012-08-31 Mitomics Inc Mitochondrial dna deletion between about residues 12317-16254 for use in the detection of cancer
ES2391235T3 (es) 2007-11-28 2012-11-22 Astellas Pharma Inc. Compuesto de indano condensado
BRPI0822111B8 (pt) * 2007-12-20 2021-05-25 Nutricia Nv composição líquida, e, uso de uma composição líquida
BRPI0822206B8 (pt) * 2008-04-25 2021-05-25 Apotex Tech Inc formulação líquida para deferiprona com um sabor agradável.
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
JP5426918B2 (ja) * 2009-04-20 2014-02-26 株式会社 伊藤園 ウリジンを含有する抗疲労剤又は体力向上剤
JP2012531411A (ja) 2009-06-25 2012-12-10 アンペア ライフ サイエンシーズ，インコーポレイテッド トコトリエノールまたはトコトリエノール濃縮抽出物を用いた広汎性発達障害の処置
CN102712591B (zh) 2009-07-03 2014-06-25 阿普泰克斯科技公司 3-羟基吡啶-4-酮的氟化衍生物
US8776268B2 (en) * 2009-12-04 2014-07-15 Harpswell Harmony LLC Hand covering(s) with dispenser and/or receptacle pocket
CA2831771C (en) 2011-03-31 2020-06-02 Takamitsu Yano Polyamide compound and pharmaceutical composition for treating mitochondrial genetic diseases
IL282198B2 (en) 2011-09-11 2025-11-01 Minovia Therapeutics Ltd Compositions of functional mitochondria and uses thereof
HK1200459A1 (en) * 2011-09-19 2015-08-07 Gencia Corporation Modified creatine compounds
WO2014187946A1 (en) 2013-05-24 2014-11-27 Nestec S.A. Treatment or prevention of autism disorders using menthol, linalool and/or icilin
KR101636946B1 (ko) * 2013-07-29 2016-07-06 한국생명공학연구원 오로트산을 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물
EA201792261A1 (ru) 2015-05-29 2018-04-30 Зе Боард Оф Трастис Оф Зе Лилэнд Стэнфорд Джуниор Юниверсити Нуклеозидные вещества для уменьшения вредной активности генов, содержащих удлиненные нуклеотидные повторы
CA2991271C (en) * 2015-06-05 2023-10-17 Fundacio Hospital Universitari Vall D'hebron - Institut De Recerca Treatment of mitochondrial diseases
WO2017062992A1 (en) * 2015-10-08 2017-04-13 Retrotope, Inc. Improving quality of mitochondrial dna measurements for use in assessing mitochondrial dysfunctions
US20180318381A1 (en) * 2015-10-23 2018-11-08 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Methods of Treatment of Rhabdomyolysis
EP3389646A1 (en) 2015-12-17 2018-10-24 BioElectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
WO2017123823A1 (en) * 2016-01-12 2017-07-20 Bioelectron Technology Corporation Alkyl-, acyl-, urea-, and aza-uracil sulfide:quinone oxidoreductase inhibitors
CA3016729A1 (en) 2016-03-03 2017-09-08 Bill Elliot Cham Glycoalkaloid combinations and various uses thereof
WO2018035380A1 (en) 2016-08-17 2018-02-22 Solstice Biologics, Ltd. Polynucleotide constructs
GB2568849B (en) * 2016-09-01 2022-08-10 Nutrition 21 Llc Magnesium biotinate compositions and methods of use
CN107412731B (zh) * 2017-05-17 2020-06-05 广州弘宝元生物科技有限公司 Ul43蛋白在制备预防和治疗线粒体功能障碍的药物中的应用
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
CN111094327A (zh) * 2017-08-16 2020-05-01 Lgv1有限公司 Bpifb4蛋白的用于神经元疾病和损伤的vtft同种型
IL276236B2 (en) * 2018-02-01 2025-12-01 Wellstat Therapeutics Corp Compositions and devices comprising uridine and the d enantiomer of beta-hydroxybutyrate and a cationic counterion
US20210375467A1 (en) * 2018-06-26 2021-12-02 Ribonova Inc. Systems and Methods for Computing Measurements for Mitochondrial Diseases
US20200022432A1 (en) * 2018-07-21 2020-01-23 Sheryl K. Bailey Mobile Pocket Glove and Non-gender Hand Wallet
WO2020021541A1 (en) * 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy with stem cells enriched with functional mitochondria
US12329781B2 (en) 2018-07-22 2025-06-17 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of renal diseases
WO2020021535A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of ocular diseases
WO2020021539A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of muscle diseases
EP3823644A4 (en) 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. MITOCHONDRIAL AUGMENTATION THERAPY OF PANCREATIC DISEASES
US12502408B2 (en) 2018-07-22 2025-12-23 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
JP7524157B2 (ja) 2018-07-22 2024-07-29 ミノヴィア セラピューティクス リミテッド 脳疾患のミトコンドリア増強療法
WO2020021489A2 (en) 2018-07-27 2020-01-30 University Of Sharjah Discovery of novel first in class nature-inspired compounds targeting the mitochondrial function and pharmaceutical composition thereof
EP3773012B1 (en) 2019-04-18 2021-06-30 Simo Rasi Composition for use in prevention or reduction of oxidative stress and neurodegenerative diseases
US11446303B2 (en) 2019-06-21 2022-09-20 Tosk, Inc. Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
MX2022012157A (es) 2020-03-31 2023-02-15 Minovia Therapeutics Ltd Celulas geneticamente modificadas enriquecidas con mitocondrias y usos de estas.
ES3060948T3 (en) 2020-09-14 2026-03-30 Pharma Cinq Llc 2',3'-diacetyluridine substituted with acetoacetyl at the 5' position
EP3970713A1 (en) 2020-09-16 2022-03-23 GV Squared S.r.l. Pharmaceutical composition comprising uridine and pyruvate for regulating the profileration, activity and survival of immune cells
CN116546989A (zh) * 2020-10-09 2023-08-04 阿达尔克斯制药有限公司 N-乙酰半乳糖胺（GalNAc）来源的化合物和寡核苷酸
IL302000A (en) * 2020-10-09 2023-06-01 Adarx Pharmaceuticals Inc compounds and oligonucleotides derived from N-acetylgalactosamine
CN116437930A (zh) * 2020-10-30 2023-07-14 上海岸阔医药科技有限公司 尿苷衍生物在制备药物中的应用
DK4255563T3 (da) 2020-12-01 2026-03-16 Pharma Cinq Llc 5´-o-phenylacetyluridin og terapeutisk anvendelse
WO2022145438A1 (ja) * 2020-12-28 2022-07-07 ヤマサ醤油株式会社 ＰＧＣ－１α発現促進剤、筋肉増強剤及びミトコンドリア賦活剤
US12661369B2 (en) * 2020-12-28 2026-06-23 Yamasa Corporation Muscular atrophy inhibitor and method for inhibiting muscular atrophy
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
US11491130B2 (en) 2021-02-05 2022-11-08 Retrotope, Inc. Methods of treating amyotrophic lateral sclerosis
US11510889B2 (en) 2021-02-05 2022-11-29 Retrotope, Inc. Methods for inhibiting the progression of neurodegenerative diseases
CN117529326A (zh) * 2021-02-21 2024-02-06 制药五有限责任公司 用于共同递送尿苷和酮亮氨酸的组合物和化合物
EP4294405A4 (en) 2021-02-21 2025-01-29 Pharma Cinq, LLC COMPOSITIONS AND COMPOUNDS FOR CO-ADMINISTRATION OF URIDINE AND KETOLEUCINE
WO2022258873A1 (es) * 2021-06-09 2022-12-15 Hospital Sant Joan De Deu Combinación nutracéutica y su uso para el tratamiento de trastornos neurológicos
CN113413394B (zh) * 2021-07-27 2022-07-01 陈玉松 5’-单磷酸核苷酸及其混合物在制备改善线粒体功能药物或食品中的应用
CN113577092B (zh) * 2021-07-30 2022-07-01 陈玉松 一种延缓衰老的含核苷酸的组合物及其制备方法和应用
CN115737666B (zh) * 2022-11-24 2024-03-26 暨南大学 尿苷二磷酸葡萄糖在制备延缓衰老产品中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB817877A (en) * 1957-01-30 1959-08-06 Ici Ltd New pyrimidine derivatives
GB1297398A (da) 1969-08-06 1972-11-22
US4600573A (en) * 1983-01-17 1986-07-15 Research Corporation Compositions and method for alleviating the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea
JPS60126221A (ja) 1983-12-14 1985-07-05 Toyama Chem Co Ltd 抗腫瘍組成物
JPS60174797A (ja) 1984-02-21 1985-09-09 Funai Corp Ν−アロイルチミジン誘導体ならびに抗腫瘍活性物質の毒性低下剤
AU586220B2 (en) * 1984-12-20 1989-07-06 Memorial Hospital For Cancer And Allied Diseases Composition and method for treatment of tumors with udpg
IT1188178B (it) * 1985-07-05 1988-01-07 Bioresearch Spa Sali della citidin-difospocolina particolarmente idonei per uso orale
US5736531A (en) 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
EP0339075B1 (en) * 1987-10-28 1993-08-18 Pro-Neuron, Inc. Acylated uridine and cytidine and uses thereof
US7173017B1 (en) * 1987-10-28 2007-02-06 Wellstat Therapeutics Corporation Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
IT1219667B (it) 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
IT1241984B (it) * 1990-06-13 1994-02-02 Polifarma Spa Impiego di uridina nel trattamento farmacologico delle complicazioni periferiche del diabete
US5658956A (en) * 1991-03-01 1997-08-19 Warner-Lambert Company Bioadhesive-wound healing compositions and methods for preparing and using same
IT1248528B (it) * 1991-06-21 1995-01-19 Pierrel Spa Derivati di eteri e tioeteri (etero) aromatici aventi attivita` antiiperlipidemica, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
WO1993024650A1 (en) 1992-05-28 1993-12-09 Monash University Therapeutic compositions
AU6081294A (en) 1993-05-14 1994-12-12 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
CN101066276A (zh) * 1994-07-01 2007-11-07 威尔斯塔特医疗公司 用于治疗全身性炎症和炎性肝炎的嘧啶核苷酸前体
CN1156409A (zh) * 1994-07-01 1997-08-06 普罗神经细胞有限公司 用于治疗全身性炎症和炎性肝炎的嘧啶核苷酸前体
EP0804183B1 (en) 1994-11-08 2006-07-05 Avicenda Group, Inc. Use of creatine or creatine analogs for the treatment of huntigton's disease, parkinson's disease and amyotrophic lateral sclerosis
RU2102985C1 (ru) * 1995-11-10 1998-01-27 Владимир Константинович Васильев Способ подавления гиперактивных клеток
IT1290781B1 (it) * 1996-05-28 1998-12-10 Polifarma Spa Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
US5906996A (en) * 1996-08-21 1999-05-25 Murphy; Michael A. Tetramine treatment of neurological disorders
DK1870103T3 (da) 1998-07-31 2010-01-11 Massachusetts Inst Technology Anvendelse af uridin i kombination med cholin i behandling af hukommelsesforsstyrrelse
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US20040224920A1 (en) 1999-02-23 2004-11-11 The Regents Of The University Of California Methods of treatment of mitochondrial disorders
BR0008447A (pt) 1999-02-23 2002-01-15 Univ California Métodos de tratamento de distúrbios mitocondriais
ITMI20020809A1 (it) * 2002-04-17 2003-10-17 Univ Degli Studi Milano Metodo per la selezione di composti utili nel trattamento della coreadi huntington
JP4243830B2 (ja) 2002-10-18 2009-03-25 セイコーエプソン株式会社 定着装置、およびそれを用いた画像形成装置

Also Published As

Publication number Publication date
HUP0103255A2 (hu) 2002-04-29
JP2002523434A (ja) 2002-07-30
KR20010085746A (ko) 2001-09-07
NZ597270A (en) 2013-06-28
US20110144051A1 (en) 2011-06-16
EP2295063A3 (en) 2011-09-14
US6472378B2 (en) 2002-10-29
BR9913319A (pt) 2001-05-22
HK1037303A1 (en) 2002-02-08
WO2000011952A1 (en) 2000-03-09
NZ586365A (en) 2012-01-12
EP1109453B1 (en) 2012-07-25
CA2696878C (en) 2016-08-16
KR20070091683A (ko) 2007-09-11
PT1109453E (pt) 2012-11-05
US20070010479A1 (en) 2007-01-11
US20010005719A1 (en) 2001-06-28
ES2393065T3 (es) 2012-12-18
RU2279880C2 (ru) 2006-07-20
KR101208016B1 (ko) 2012-12-04
IL141429A (en) 2013-10-31
CN100361665C (zh) 2008-01-16
US20010016576A1 (en) 2001-08-23
CA2696878A1 (en) 2000-03-09
CN1328417A (zh) 2001-12-26
AU6021999A (en) 2000-03-21
US7582619B2 (en) 2009-09-01
US6956028B2 (en) 2005-10-18
HUP0103255A3 (en) 2003-01-28
CY1113610T1 (el) 2016-06-22
EP1109453A4 (en) 2006-11-02
US20050203066A1 (en) 2005-09-15
AU753203B2 (en) 2002-10-10
CN1636572A (zh) 2005-07-13
EP1109453A1 (en) 2001-06-27
CA2341700C (en) 2010-06-15
CA2931872A1 (en) 2000-03-09
CA2341700A1 (en) 2000-03-09
JP2010195837A (ja) 2010-09-09
CA2931872C (en) 2019-08-06
JP4717209B2 (ja) 2011-07-06
CN1636572B (zh) 2012-09-05
RU2006108077A (ru) 2007-09-20
HU230066B1 (hu) 2015-06-29
IL141429A0 (en) 2002-03-10
EP2295063A2 (en) 2011-03-16
ZA200101565B (en) 2002-05-15
EP2295063B1 (en) 2017-04-26
US8067392B2 (en) 2011-11-29
EP2295063A8 (en) 2011-05-18

Similar Documents

Publication Publication Date Title
DK1123313T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af anæmi
NO20011613L (no) Sammensetninger og fremgangsmåte for WT1-spesifikk immunterapi
DK0971735T3 (da) Fremgangsmåder og præparater til behandling af inflammatorisk tarmsygdom
DK1003479T3 (da) Fremgangsmåde og sammensætninger til behandling af allergiske senfasereaktioner og inflammatoriske sygdomme
NO20003096L (no) Sammensetninger og fremgangsmÕter for behandling av ADD
NO20012916D0 (no) Sammensetninger og fremgangsmåter for behandling av anorektale forstyrrelser
NO991676D0 (no) FremgangsmÕter og sammensetninger for immunmodulering
DK1242095T3 (da) Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf
DK0990391T3 (da) Phytosterolholdig fedtsammensætning
NO20005913L (no) Legemiddelsammensetning
DK0781136T3 (da) Forbindelser og fremgangsmåder til behandling af cancer
DE69730092D1 (de) Photovernetzbare Siliconzusammensetzungen
NO20024610D0 (no) Synergistiske metoder og blandinger for behandling av kreft
NO20032753D0 (no) Forbindelse og anvendelse derav
NO20006488D0 (no) Sammensetning og anvendelse
PT1139761E (pt) Composicoes herbicidas e concentrados tensioactivos
ATE271598T1 (de) Desinfektionszusammensetzungen und verfahren
NO985385D0 (no) Bitumensammensetninger og fremgangsmÕte for fremstilling derav
DK199800837A (da) Anlæg til behandling af emner
DE69900340D1 (de) Einrichtung zur Laserbehandlung
DE69908232D1 (de) Laserbehandlungsvorrichtung
DK1461047T3 (da) Sammensætninger og fremgangsmåde til behandling af dyr
EP1073333A4 (en) S-RABEPRAZOLE COMPOSITIONS AND METHODS
NO20010464D0 (no) Fremgangsmåter og sammensetninger for behandling av gastroösofrageal-reflukssyndrom
NO20013085D0 (no) Fosfororganiske forbindelser og deres anvendelse